Invention Grant
- Patent Title: Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies
-
Application No.: US15495388Application Date: 2017-04-24
-
Publication No.: US10421811B2Publication Date: 2019-09-24
- Inventor: Jiali Du , Ambarish Shah
- Applicant: MedImmune, LLC
- Applicant Address: US MD Gaithersburg
- Assignee: MEDIMMUNE, LLC
- Current Assignee: MEDIMMUNE, LLC
- Current Assignee Address: US MD Gaithersburg
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K39/395 ; C07K16/28 ; A61K39/00
Abstract:
Provided herein are compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-L1 antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided.
Public/Granted literature
- US20170306025A1 COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES Public/Granted day:2017-10-26
Information query
